跳至主要内容
临床试验/NCT02093286
NCT02093286已完成不适用

Phase IV, Study of Safety Profile Following Pentabio Vaccination in Indonesian Infants

PT Bio Farma4 个研究点 分布在 1 个国家目标入组 4,000 人开始时间: 2014年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
PT Bio Farma
入组人数
4,000
试验地点
4
主要终点
Any serious adverse event occurring from inclusion until 30 minutes after the injection

研究概览

简要总结

To assess any serious systemic reaction within 30 minutes after Pentabio immunization

详细描述

Any local and systemic reaction after Pentabio immunization

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
2 Months 至 11 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Immunization with Pentabio vaccine
  • Parents already understood the consequences to be involved in this study and having signed the informed consent form
  • Parents agree and willing to fill in the Diary Card, to record all the reactions after immunization

排除标准

  • Given simultaneously with other vaccines or with the interval less than 1 month with other vaccination except OPV/IPV.

结局指标

主要结局

Any serious adverse event occurring from inclusion until 30 minutes after the injection

时间窗: 30 minutes

local and systemic reaction

次要结局

  • Percentage of local and systemic events occurring within 72 hours after each injection(72 hours)
  • Percentage of local and systemic events occurring from 72 hours up to 28 days following injection.(25 days)
  • Percentage of serious adverse events within 28 days after injection(28 days)

研究者

发起方
PT Bio Farma
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

已完成
4 期
A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of AgePoliomyelitis
NCT02580201Fidec Corporation154
尚未招募
4 期
Study to evaluate the effects of the COVID-19 (inactivated) vaccine of the Instituto Butantan in immucompromised personsChronic kidney diseaseRespiratory diseasesCOVID-19Immunocompromised hostsTransplant recipientsLiver cirrhosisNeoplasmsPrimary immunodeficiency diseasesC01.918
RBR-9ksh5f4Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
进行中(未招募)
1 期
A clincal study to evaluate the safety of a polio vaccine type 2 given orally in healthy children aged 1 to 5 years previously treated with inactivated polio vaccine in Lithuaniaevaluation of safety of SABIN mOPV2 in healthy IPV-vaccinated children of 1 – 5 years of age (Polio disease)MedDRA version: 18.0Level: LLTClassification code 10036016Term: Poliomyelitis NOSSystem Organ Class: 100000004862
EUCTR2015-003544-39-LTFIDEC - Fighting Infectious Diseases in Emerging Countries
进行中(未招募)
1 期
A vaccine study in healthy adults to evaluate the safety and immune response of a licensed oral polio vaccine containing the polio vaccine 2 straiPolio diseaseMedDRA version: 18.0Level: HLTClassification code 10036017Term: Poliomyelitis viral infectionsSystem Organ Class: 100000004862
EUCTR2015-003325-33-BEniversity of Antwerp100
进行中(未招募)
1 期
A vaccine study in healthy adults to evaluate the safety and immune response of a licensed oral polio vaccine containing 3 polio vaccine strains.Historic tOPV can result in the emergence of circulating vaccine-derived polioviruses (cVDPVs): the attenuated strains of poliovirus from the vaccine infect un-immunized individuals, replicate, circulate in the population, and may eventually mutate enough to become virulent and effect vaccine-associated paralytic poliomyelitis (VAPP).MedDRA version: 18.0Level: HLTClassification code 10036017Term: Poliomyelitis viral infectionsSystem Organ Class: 100000004862
EUCTR2015-003324-32-BEniversity of Antwerp128